Catalyst Ev To Operating Cash Flow from 2010 to 2025
| CPRX Stock | USD 24.35 0.10 0.41% |
EV To Operating Cash Flow | First Reported 2010-12-31 | Previous Quarter 8.16425415 | Current Value 8.57 | Quarterly Volatility 21.48635274 |
Check Catalyst Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Catalyst Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 5 M, Other Operating Expenses of 311.4 M or Operating Income of 204.9 M, as well as many indicators such as Price To Sales Ratio of 4.78, Dividend Yield of 0.0 or PTB Ratio of 3.23. Catalyst financial statements analysis is a perfect complement when working with Catalyst Pharmaceuticals Valuation or Volatility modules.
Catalyst | Ev To Operating Cash Flow | Build AI portfolio with Catalyst Stock |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Catalyst Stock Analysis
When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.